Connected Drug Delivery Devices Market Size, Trends Rising Advancement in Technology & Data Standardization Drive the Growth 2030

Connected drug delivery devices are the wireless connected and smart electronic devices that allow patient-administrated therapy. Delivering drugs through connected devices, such as auto-injectors, smart inhalers, and closed-loop solutions, has been documented as a potential way of improving patient adherence and reducing dosing errors, particularly in the home setting. Also, these devices are used for the treatment of various diseases such as multiple sclerosis, diabetes, liver & renal transplant recipients, hepatitis C, hypertension, asthma, tuberculosis, and clinically isolated syndrome.

Connected drug delivery devices help physicians to monitor the compliance of patients to the therapy prescribed by them as well as to modify or make any advancement in the treatment of the patient treatment as required. Increasing number of initiatives to create awareness regarding complexities caused by over dosage or under dosage of medicines is expected to promote the adoption of connected drug delivery devices. Patients with chronic diseases, such as asthma and diabetes, are facing challenges in managing medications, adherence to prescriptions, visiting healthcare providers, and maintaining a balanced diet. Connected drug delivery devices can be useful for self-management.

As these devices can aid in patient adherence to prescribed treatments, which is likely to significantly increase their adoption.
The global connected drug delivery devices market generated $290.3 million in 2021, and is estimated to reach $2.1 billion by 2030, witnessing a CAGR of 24.3% from 2022 to 2030. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.

Download Free Sample Report- https://www.alliedmarketresearch.com/request-sample/26467

Covid-19 Scenario:
• The outbreak of the Covid-19 pandemic made the healthcare system strenuous and created a respiratory state of emergency for patients with severe respiratory conditions.
• Digital health, telemedicine, and remote monitoring made it possible to keep these patients safer in their homes by avoiding unnecessary in-person office and emergency room visits, improving engagement and overall health, and providing more direct communication between patients and their providers.

The report offers a detailed segmentation of the global connected drug delivery devices market based on type, technology, end use, and region. The report provides an analysis of each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants in determining the sub-segments to be tapped on to achieve growth in the coming years.

By type, the injectables segment held the lion's share of nearly three-fifths of the global Connected Drug Delivery Devices market in 2021 and would dominate in terms of revenue during the forecast period. However, the inhalation devices segment is estimated to witness the fastest CAGR of 24.95% during the forecast period. Based on the technology, the Bluetooth segment was the largest in 2021, capturing nearly two-thirds of the global market share of connected drug delivery devices and will dominate until 2030.

However, the NFC segment is estimated to witness the Faster CAGR of 24.82%. during the forecast period. Based on end use, the hospital segment was the largest in 2021, capturing nearly three-quarters of the global market share for connected drug delivery devices and would dominate in terms of revenue during the forecast period. However, the home care segment is expected to witness the fastest CAGR of 24.85% during the forecast period.

Customization Request- https://www.alliedmarketresearch.com/request-for-customization/26467

Based on region, the market in North America was the largest in 2021, accounting for more than one-third of the global connected drug delivery devices market share and would maintain a progressive revenue growth during the forecast period. However, the market in Asia-Pacific is expected to manifest the highest CAGR of 24.93% from 2022 to 2030. The other regions analyzed in the study include Europe and LAMEA.

Leading players of the global connected drug delivery devices market analyzed in the research include
Adherium, BD,
Proteus Digital Health,
Propeller Health,
F. Hoffmann-La Roche Ltd.,
Ypsomed AG,
Cohero Health, Inc.,
West Pharmaceutical Services,
Syncro Technology Corp., and AptarGroup Inc.

The report analyzes these key players of the global connected drug delivery devices market. These players have adopted various strategies such as expansion, new product launches, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments by every market player.

Know More- https://www.alliedmarketresearch.com/press-release/connected-drug-delivery-devices-market.html

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

Alied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.